(RGNX) tumbled 15% after-hours on Thursday after the company announced plans to raise $100 million through a public stock ...

Results point to potential to restore vision with drugs, non-invasively, reversibly, via a mechanism that is independent to ...

A Pittsburgh-area man is participating in a clinical trial for a medication to treat Stargardt disease, a rare retinal ...

Every living organism inherits a unique combination of traits, from eye colour and blood type to resistance against certain ...

In 2026, the FDA approved 23 brand-new medications never sold before in the U.S., covering everything from childhood genetic ...

Key Points Interested in Ocugen, Inc.? Here are five stocks we like better. Ocugen plans three late-stage retinal gene ...

Today, as co-founder Steve Johnston celebrates his birthday, A Race Against Blindness marks another milestone: helping families facing inherited blindness. The Arizona-based nonprofit, founded by ...

A newly identified retinal signaling molecule may help coordinate the eye’s response to damage, revealing a potential avenue ...

MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investmentFollowing regulatory approval, Oberland Capital to receive low single-digit capped royalties on ...

Healome Therapeutics ('Healome'), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, has closed a GBP£2 million oversubscribed seed ...

Losing eyesight is one of the greatest fears many people have as they grow older. One disease that can quietly steal vision ...

Inherited retinal degenerations are a diverse group of genetic disorders that result in progressive vision loss. Advances in ...